Peer-reviewed veterinary case report
Genes linked to platelet activation in dogs with stage B2 mitral
By Zhou, Qingqing et al.·Published in BMC veterinary research·2023·Department of Clinical Animal Medicine, China·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Differentially expressed platelet activation-related genes in dogs with stage B2 myxomatous mitral valve disease.
- Species:
- dog
Plain-English summary
A group of dogs with stage B2 myxomatous mitral valve disease (MMVD) showed changes in certain genes related to platelet activation in their blood. These dogs typically experience heart issues due to mitral regurgitation, which can lead to long-term heart problems. Researchers identified four specific genes—MDM2, ROCK1, RIPK1, and SNAP23—that were significantly altered in these dogs compared to healthy dogs. These genes could potentially serve as biomarkers to help diagnose MMVD stage B2 and understand its progression better.
People also search for: dog heart disease symptoms · myxomatous mitral valve disease in dogs · platelet activation genes in dogs · MMVD stage B2 treatment options
Abstract
BACKGROUND: Peripheral blood carries a reservoir of mRNAs that regulate cardiac structure and function potential. Although it is well recognized that the typical symptoms of Myxomatous Mitral Valve Disease (MMVD) stage B2 are long-standing hemodynamic disorder and cardiac structure remodeling caused by mitral regurgitation, the transcriptomic alterations in blood from such dogs are not understood. RESULTS: In the present study, comparative high-throughput transcriptomic profiling of blood was performed from normal control (NC) and naturally-occurring MMVD stage B2 (MMVD) dogs. Using Weighted Gene Co-expression Network Analyses (WGCNA), Gene Ontology (GO), and Kyoto Encyclopedia of Gene and Genomes (KEGG), we identified that the turquoise module was the most highly correlated with echocardiographic features and found 64 differentially expressed genes (DEGs) that were significantly enriched in platelet activation related pathways. Therefore, from the turquoise module, we selected five DEGs (MDM2, ROCK1, RIPK1, SNAP23, and ARHGAP35) that, according to real-time qPCR, exhibited significant enrichment in platelet activation related pathways for validation. The results showed that the blood transcriptional abundance of MDM2, ROCK1, RIPK1, and SNAP23 differed significantly (P < 0.01) between NC and MMVD dogs. On the other hand, Correlation Analysis revealed that MDM2, ROCK1, RIPK1, and SNAP23 genes negatively regulated the heart structure parameters, and followed the same trend as observed in WGCNA. CONCLUSION: We screened four platelet activation related genes, MDM2, ROCK1, RIPK1, and SNAP23, which may be considered as the candidate biomarkers for the diagnosis of MMVD stage B2. These findings provided new insights into MMVD pathogenesis.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/38087280/